Cerebrolysin 10×1 milliliter box
Effective, non-synthetic treatment for stroke, Alzheimer’s, dementia
Helps sports performance, cognitive function, diabetes
Cerebrolysin® could be a peptide preparation. the solution, prepared for injection or infusion, is free of proteins, lipids and antigenic properties. 1ml of Cerebrolysin® concentrate as active ingredient in solution.
Route of administration
Solution for intramuscular and intravenous injection or intravenous infusion.
The efficacy of Cerebrolysin® is proved in various animal experiments and clinical trials. Cerebrolysin® could be a brain-specific peptidergic nootropic drug ready to affect the central nervous system in a multimodal method.
In Controlled clinical trials Cerebrolysin® treatment results in an improvement within the cognitive performance and mood of patients affected by Alzheimer’s sickness. Therefore, the amount of care required by these sufferers decreases.
In these patients marked improvement is determined in 61.7% of the Cerebrolysin® – treated group (as assessed by the Clinical global Impressions scale CGI ). Another clinical test in patients with vascular dementia demonstrates improvement of memory performance within the group receiving Cerebrolysin® treatment. an improvement in the international clinical image is also detected during this illness. an extra study involving patients from
nine completely different disease entities established the effectiveness of Cerebrolysin® through the utilization of eleven psychological tests subjected to a variance analysis.
After stroke and craniocerebral truma treatment wit Cerebrolysin® results in an accelerated recovery.
Literature on Cerebrolysin® is offered upon request.
cerebrolysin® passes through the barrier . Up to eight hours after iv administration of Cerebrolysin® neurotophic activity is detected within the human long-lasting effects even after one iv administarion.
Cerebrolysin® is mostly well tolerated and possesses a very high margin of safety. In human therapeutic dosages this produces nearly no toxic symptoms. The toxicologic information are listed below.
Acute toxicity: when a single iv administration of Cerebrolysin® the subsequent LD50 values were determined (14 days observation period) :male rats68ml/kg weight , feminine rats 74ml/kg weight ; dogs, male and feminine >52.2ml/kg weight. Chronic toxicity (multiple doses over six months) rats received up to 12.5ml/kg weight daily for twenty six weeks. only moderate changes within the blood count were determined, dogs ; the very best administrated doses were 9ml/kg weight daily for twenty eight days (about ten times the human therapeutic dosage) and 4.5ml/kg weight daily for twenty six weeks (about 5 times the human therapeutic dosage): no general substance-dependent intolerance reactions were determined .
Reproductive toxicity: Cerebrolysin® was injected iv to the dams at the best attainable volumes: in no case was an alteration of the gestagenic amount determined, in rabbits. Neither embryotoxic nor teratogenic effects nor
impairments of embryonic or neonatal developments were found; no influence on the relation (F1 and F2 generations) was evident. Influence on the fertility and reproductive performance of the parent anilmals potential, result or carcinogenicity in toxicologic tests, neither in vitro nor in vivo.
• disturbances of concentration and memory
• degenerative dementias, together with Alzheimer’s illness
• vascular demenatias, eg multi-infarct dementia
• mixed types of dementia (degenerative and vascular contribution)
• sequels of stroke (ischaemic and haemorrhagic)
• posttraumatic or postoperative complaints, eg following cerebral
contusion, concussion, or neurosurgical operation.
• hypersensitivity to 1 of the parts of the drug
• status epilepticus or grand mal conulsions; a rise in the seizure
frequency could also be seen in these cases
• status epilepticus or grand mal conulsions; a rise within the seizure
frequency could also be seen in these cases
• severe impairments of renal function
Cerebrolysin® is mostly well tolerated. If injected too quick it should cause a moderate heat sensation. In extremely rare cases a hypersensitivity manifested itself as chills, headaches or as slight increase in body
temperature the reason for that is perhaps the hyperresponiveness of the patient. In no case to date has the undesirable result persisted or proven threatening to the patient.
Warning and precautionary measures
Patients with severe renal impairment should be excluded from a Cerebrolysin® medical care. Animal experimental information didn’t show any proof to teratogenic effects. there’s no clinical experience with Cerebrolysin® in women.
Therefore, unless the potential advantages outweigh any potential risk.
Cerebrolysin® shouldn’t be administered throughout preguancy and also the lactation period.
The concomitant administration of Cerebrolysin® with antidepressive medicine or MAO inhibitors will result in cumulative effects.
Dasage and administration
Cerebrolysin® is obtainable in 1ml, 5ml and 10ml ampoules and vials of 30ml and 50ml. Up to 5ml per intramuscular administration, for administration over 5ml an intravenous injection or infusion is suggested.
Cerebrolysin® can even run diluted during a normal iv solution (eg physiological saline solution, flinger’s solution, glucose 5%, dextran 40) infused slowly over about twenty to 60 minutes, Once daily application of Cerebrolysin® for a minimum of ten to twenty days are suggested. This constitutes a course of medical care. In mild cases 1-5ml, is suggested and in severe cases 10-30ml should be applied. The length of the medical care and also the individual doses on the age of the patient still as on the illness. sometimes a treatment period of 3 to four weeks is usually recommended. therapy courses is repeated many times in accordance with the clinical image of the patient till no more improvement is observed.
Keep in a secure place out the reach of kids. Store at room temperature not over 25°C, away from light.